Soleno Therapeutics Income Statement (2013-2026) | SLNO

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)																	32.66M	66.02M	91.73M	94.60M
Cost of Revenue (Quarter)																	0.70M	1.14M	0.86M	1.20M
Gross Profit (Quarter)																	31.96M	64.88M	90.87M	93.41M
Operating items
Research & Development (Quarter)	5.59M	4.97M	3.73M	3.99M	3.70M	3.77M	3.81M	5.32M	5.14M	6.04M	8.69M	14.60M	12.34M	30.14M	21.49M	13.52M	9.15M	8.40M	9.56M	11.27M
Selling, General & Administrative (Quarter)	2.46M	2.77M	2.60M	2.64M	2.47M	2.33M	2.40M	2.85M	3.17M	3.32M	4.14M	8.47M	10.89M	49.20M	37.30M	29.26M	28.24M	33.75M	40.88M	50.37M
Other Operating Expenses (Quarter)	3.03M	0.55M	-3.33M	-0.86M	0.62M	0.13M	-0.60M	0.30M	0.31M	1.02M	1.08M	0.40M	1.64M	0.88M	0.33M	2.97M	1.80M	1.75M	1.72M	1.68M
Operating Expenses (Quarter)	11.09M	8.29M	3.00M	5.77M	6.78M	6.24M	5.61M	8.47M	8.62M	10.38M	13.91M	23.48M	24.87M	80.21M	59.12M	45.74M	39.18M	43.91M	52.15M	63.33M
Operating Income (Quarter)	-11.09M	-8.29M	-3.00M	-5.77M	-6.78M	-6.24M	-5.61M	-8.47M	-8.62M	-10.38M	-13.91M	-23.48M	-24.87M	-80.21M	-59.12M	-45.74M	-6.53M	22.11M	39.58M	31.28M
EBIT (Quarter)	-11.09M	-8.29M	-3.00M	-5.77M	-6.78M	-6.24M	-5.61M	-8.47M	-8.62M	-10.38M	-13.91M	-23.48M	-24.87M	-80.21M	-59.12M	-45.74M	-6.53M	22.11M	39.58M	31.28M
Non-operating items
Interest & Investment Income (Quarter)								0.11M	0.15M	0.17M	2.14M	2.08M	3.01M	3.60M	3.37M	3.33M	3.19M	5.30M	5.13M	4.93M
Other Non Operating Income (Quarter)	0.04M	0.03M	0.03M	0.02M	0.05M	0.10M	0.12M	0.11M	0.15M	0.17M	2.14M
Non Operating Income (Quarter)	0.10M	0.15M	0.17M	0.05M	0.05M	0.10M	0.12M	0.11M	0.15M	-0.48M	2.61M	2.08M	3.01M	3.60M	3.13M	1.97M	1.82M	3.91M	3.78M	3.63M
Net income details
EBT (Quarter)	-11.70M	-8.34M	-54.32M	-6.22M	-7.13M	-6.48M	-62.63M	-8.47M	-8.48M	-58.17M	-11.50M	-100.06M	-91.99M	-173.76M	-55.73M	-43.77M	-173.92M	-86.16M	43.49M	34.91M
Tax Provisions (Quarter)																				3.54M
Profit After Tax (Quarter)	-10.99M	-8.14M	-2.83M	-5.72M	-6.72M	-6.13M	-5.49M	-8.36M	-8.47M	-10.86M	-11.30M	-21.40M	-21.85M	-76.62M	-55.62M	-43.77M	-4.71M	26.01M	43.41M	31.38M
Income from Non-Controlling Interests (Quarter)												-0.10M	-0.05M	1.05M	-0.54M	-0.14M	-0.15M	0.26M	0.07M	-2.23M
Income from Continuing Operations (Quarter)	-11.70M	-8.34M	-54.32M	-6.22M	-7.13M	-6.48M	-62.63M	-8.47M	-8.48M	-58.17M	-11.50M	-100.06M	-91.99M	-173.76M	-55.73M	-43.77M	-173.92M	-86.16M	43.49M	31.38M
Income from Discontinued Operations (Quarter)
Consolidated Net Income (Quarter)	-11.70M	-8.34M	-54.32M	-6.22M	-7.13M	-6.48M	-62.63M	-8.47M	-8.48M	-58.17M	-11.50M	-100.06M	-91.99M	-173.76M	-55.73M	-43.77M	-173.92M	-86.16M	43.49M	31.38M
Income towards Parent Company (Quarter)	-11.70M	-8.34M	-54.32M	-6.22M	-7.13M	-6.48M	-62.63M	-8.47M	-8.48M	-58.17M	-11.50M	-100.06M	-91.99M	-173.76M	-55.73M	-43.77M	-173.92M	-86.16M	43.49M	31.38M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-11.70M	-8.34M	-54.32M	-6.22M	-7.13M	-6.48M	-62.63M	-8.47M	-8.48M	-58.17M	-11.50M	-100.06M	-91.99M	-173.76M	-55.73M	-43.77M	-173.92M	-86.16M	43.49M	31.38M
Additional items
EPS (Basic) (Quarter)	-2.20	-1.57	-10.21	-1.17	-0.89	-0.80	-7.46	-0.90	-0.81	-5.09	-0.70	-2.76	-2.38	-4.15	-1.39	-0.95	-3.45	-1.62	0.86	0.60
EPS (Diluted) (Quarter)	-2.20	-1.57	-10.21	-1.17	-0.89	-0.80	-7.46	-0.90	-0.81	-5.09	-0.70	-2.76	-2.38	-4.15	-1.39	-0.95	-3.45	-1.57	0.83	0.59
Shares Outstanding (Quarter)	5.32M	5.32M	5.32M	5.33M	8.01M	8.09M	8.40M	9.45M	10.42M	11.44M	16.49M	36.21M	38.63M	41.88M	40.18M	46.18M	50.48M	53.33M	50.82M	52.09M
Shares Outstanding (Diluted) (Quarter)	5.32M	5.32M	5.32M	5.33M	8.01M	8.09M	8.40M	9.45M	10.42M	11.44M	16.49M	36.21M	38.63M	41.88M	40.18M	46.18M	50.48M	54.92M	52.38M	53.07M
Shares Outstanding (Entity) (Quarter)	5.32M	5.32M	5.32M	5.33M	8.01M	8.16M	8.16M	8.17M	9.14M	11.44M	16.49M
EBITDA (Quarter)	-11.09M	-8.29M	-3.00M	-5.77M	-6.78M	-6.24M	-5.61M	-8.47M	-8.62M	-10.38M	-13.91M	-23.48M	-24.87M	-80.21M	-59.12M	-45.74M	-6.53M	22.11M	39.58M	31.28M
Interest Expenses (Quarter)	0.61M	0.05M	51.31M	0.45M	0.35M	0.25M	57.02M	0.12M	532.00	47.96M	-0.26M	78.66M	70.13M	97.14M	-0.02M	1.36M	170.59M	113.56M	1.22M	27.25M
Tax Rate (Quarter)																				10.13%

Research Tools

Developers

Soleno Therapeutics Income Statement (2013-2026) | SLNO

Research Tools

Developers

Soleno Therapeutics Income Statement (2013-2026) | SLNO

Create an account

Sign In

Reset Password